6533b825fe1ef96bd12830f2
RESEARCH PRODUCT
Phase I/II Trial of High-Dose Cytosine Arabinoside and Mitoxantrone in Adult Refractory Acute Myeloid Leukemia
W.-d. LudwigWolfgang HiddemannR. Donhuijsen-antTh. BüchnerH. KreutzmannE. LengfelderH.-j. FuhrK. Straifsubject
OncologyMitoxantronemedicine.medical_specialtyAcute leukemiabusiness.industryMyeloid leukemiaDiseasemedicine.diseaseLeukemiachemistry.chemical_compoundRefractorychemistryhemic and lymphatic diseasesInternal medicinemedicineCytarabinebusinessCytosinemedicine.drugdescription
In spite of a high initial response rate of 60% –80% the vast majority of adult patients with acute myeloid leukemia (AML) still cannot be cured of the disease and ultimately die from recurrent and refractory leukemia. The development of new therapeutic approaches and of more effective drugs therefore seems warranted.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1987-01-01 |